Titan Pharmaceuticals Inc (TTNP)

[Doctor Detroit]

Yeah, it's starting to get a little confusing with all the different development studies.

Opiant is best known for developing NARCAN. They did it quickly: it was conceived, licensed, developed, approved by the FDA, and commercialized in less than three years.

But they also have a lot of experience with "mu opioid receptor" antagonists, which completely block opioid's effect and are meant for people who are completely clean from opioids. (Vivitrol is another opioid antagonist; Buprenorphine, on the other hand, is an agonist...it allows some opioid effect). Opiant has two proprietary, patented opioid antagonists (OPNT 001 and OPNT 002) that they are currently testing for alcohol abuse, cocaine abuse and binge eating disorder. I would guess they want to test OPNT 001 and OPNT 002 in implant formation for opioid addiction. That's what they bring to the table.

Cara's peripherally acting kappa opioid receptor agonist, called CR845, is not an antagonist...it allows some opioid effect. It hasn't been developed for opioid abuse, but for chronic pain. It looks like initial testing shows it is not addictive, but is best used in IV form (problems with bioavailability). So I'm guessing they are working with Titan to see if they can use it through an implant for pain.